key: cord-0800463-2vn51ti3 authors: Feyaerts, Adam F.; Luyten, Walter title: Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19? date: 2020-07-25 journal: Nutrition DOI: 10.1016/j.nut.2020.110948 sha: af01bdf59cd7af962268f4902a90bce2080a9d1a doc_id: 800463 cord_uid: 2vn51ti3 SARS‐CoV‐2 causes the potentially fatal COVID-19 disease. Already during the outbreak of SARS‐CoV‐1, the use of vitamin C was suggested. Many patients with severe COVID-19 have elevated levels of the mediators interleukin-6 and endothelin-1. These mediators may explain the age-dependence of COVID-19 pneumonia, the preponderance of male and obese or hypertensive patients, as well as of persons of colour, and smokers. There is clear evidence that vitamin C in high doses can reduce these mediators. Vitamin C is cheap and safe. Hence using a relatively low dose of vitamin C as prophylaxis, and in case of severe COVID-19 disease, an (intravenous) high-dose regimen may be beneficial. Ongoing clinical trials are expected to provide more definitive evidence A novel human coronavirus has recently been identified, i.e. SARS-CoV-2, which causes the potentially fatal COVID-19 disease 1 . SARS-CoV-2 is only the latest of three human coronavirus strains (the others being: SARS-CoV-1 and MERS-CoV) that can cause severe illness, but it is the first to cause a pandemic 2 . Major efforts are under way worldwide in the search for pharmaceutical interventions, but no therapies with proven efficacy to treat COVID-19 are currently available, although e.g. (hydroxy-)chloroquine with and without zinc supplementation is being used off-label as prophylaxis or treatment [3] [4] [5] [6] [7] [8] [9] [10] [11] . Approximately 5% of the patients diagnosed with COVID-19 become critically ill and require advanced respiratory support with (non-)invasive mechanical ventilation and added oxygen as the standard of care 4, 12, 13 . A recent report suggests that hyperbaric oxygen therapy could be a promising alternative, which is interesting in light of the suggestion that some SARS-CoV-2 proteins may interfere with haemoglobin function 14, 15 More than a 100 animal studies indicated that a daily dose of a few grams of vitamin C may alleviate or prevent infections 17 . Already during the outbreak of SARS-CoV-1 (2003); the use of vitamin C, an essential micronutrient for humans and a free radical scavenger, was suggested as a non-specific treatment for severe viral respiratory tract infections 4, 18, 19 . Indeed, it is known that vitamin C supports various cellular functions of both the innate and the adaptive immune system, including modifying susceptibility to various viral infections, and by influencing inflammation 20, 21 . Moreover, in chick embryo tracheal organ cultures, vitamin C increased resistance to infection by a coronavirus 22 . Additionally, vitamin C treatment restores the stress response and improves the survival of stressed humans 23 . However, a recent preliminary open-label study in patients with sepsis and acute respiratory distress syndrome showed that a 96-hour infusion of high dose vitamin C compared to placebo did not significantly improve organ dysfunction scores or change markers of inflammation 24 . In contrast, early use of intravenous vitamin C in combination with corticosteroids and thiamine proved effective in preventing progressive organ dysfunction and in reducing the mortality of patients with severe sepsis and septic shock 25 . Intravenous hydrocortisone alone, however, had a similar effect on the survival of patients with septic shock as did the combination of high-dose vitamin C, hydrocortisone and thiamine 26 , suggesting little added value of vitamin C in sepsis. However, vitamin C may have beneficial effects in adults and children with pneumonia 27 , as well as of patients in intensive care units 28 . A Cochrane Systematic Review concludes that 1-2 g vitamin C per day is safe, inexpensive and has a consistent effect on the duration and severity of the common cold 29, 30 . It furthermore concludes that mega-dose prophylaxis is not rationally justified for community use, although it may be justified at times e.g. in periods of heavy physical exercise. Evidence is accumulating that many severely ill COVID-19 patients have elevated cytokine levels, including of the multifunctional inflammatory key molecule interleukin-6 (IL-6), resembling the cytokine storm described in SARS and MERS 1, [31] [32] [33] [34] [35] [36] . This may indicate that high mortality is due to virus-driven hyperinflammation. Preliminary data suggest that COVID-19 pneumonia is a late-stage complication caused by the hyperactivation of immune effector cells, and treatment with (intravenous) high-dose vitamin C has been proposed to suppress these effectors 37 . Treatment with vitamin C decreases IL-6 and it blocks in vivo the release of IL-6 in the endothelium induced by endothelin-1 (ET-1) in humans 23, 38 . ET-1 is a potent vasoconstrictor peptide, but it is also recognized as a proinflammatory cytokine, including in the lung, and its increased expression has been associated with pneumonia, pulmonary hypertension, interstitial lung fibrosis and acute respiratory distress syndrome [39] [40] [41] . In severe COVID-19 patients who survive the disease, cytokine levels, including IL-6, gradually return later in the course of the disease to levels comparable to those in mild cases 33 pneumonia 45 , which is thought to be a late response of the immune system to the viral infection. This may seem counterintuitive since many aspects of the immune response decrease in the elderly. However, both in mice and humans, serum levels of IL-6 increase with age [46] [47] [48] . Overexpression of IL-6 in older mice is harmful, and during systemic inflammation IL-6 strongly increases; moreover, this increase is prolonged with age in multiple tissues (e.g. lungs, heart, and plasma) 49 . Elevated levels of IL-6 are associated with a higher frequency of multiple organ failure 36, 50 . Gene expression analysis revealed that older people mount a stronger immune response, including IL-6, to SARS-CoV-1, and there is no reason to assume this would be different for SARS-CoV-2 32,51 . IL-6 or ET-1 may not only explain the age-dependence of COVID-19 pneumonia, but also the preponderance of male and obese or hypertensive patients, as well as of persons of colour, and smokers. Almost three out of four critically ill COVID-19 patients are male (70.8%; n=6,814) 16 Adipocytes also produce IL-6 and this may explain why obese individuals have higher endogenous levels of C-reactive protein 53, 57 . It seems that more non-white than white people become critically ill 45 . There is some evidence that ET-1 levels are significantly increased in black men compared to white men 58 . Also, COVID-19 patients who smoke seem to be more susceptible, and it is known that ET-1 potentiates smoke-induced acute lung inflammation 59 . Finally, there is some preliminary evidence that a need for mechanical ventilation was very strongly associated with elevated IL-6 levels, and that moderately elevated IL-6 levels are sufficient to identify COVID-19 patients at high risk of respiratory failure 1,60 . Given the critical role of IL-6 in severe COVID-19 disease, and the demonstrated ability of vitamin C to prevent the rise of IL-6 in several (pro)inflammatory conditions 61 , it is logical to assume that vitamin C may benefit COVID-19 patients. Moreover, since vitamin C inhibits the increase of a range of inflammatory cytokines 21, 62, 63 , it may be therapeutically superior to blockers of individual cytokine mediators. A randomized placebo-controlled study showed that vitamin C (500 mg twice daily) alleviates the inflammatory status by reducing, amongst others, IL-6 and C-reactive protein in hypertensive and/or diabetic obese patients 64 . This suggests that vitamin C may also be of use in severe forms of COVID-19 65 . Vitamin C may also inhibit the the ability of neutrophils to form neutrophil extracellular traps, which may contribute to organ damage and mortality in COVID-19 66 . Finally, vitamin C may have beneficial effects on the thrombotic or thromboembolic disease commonly found in COVID-19 patients [67] [68] [69] . More than 10 new COVID-19 related clinical trials have been started or are announced since February 2020 to investigate the therapeutic effect of vitamin C alone or in combination with one or more other substances e.g. vitamin D, zinc (gluconate), hydroxycholoquine (sulphate), azithromycin 70 . For example, a clinical trial is ongoing in which vitamin C (6 to 12 g /day) is being administered intravenously for moderate and severe cases of COVID-19 pneumonia (NCT04264533). It is not always clear how the dose ranges were established in these different studies. A recent review, however, suggests that (much) higher intravenous vitamin C doses may be necessary for reduction of cytokines storm in acute respiratory distress syndrome 63 . COVID-19 pneumonia and its progression to respiratory failure appear to be driven by an immune hyperreaction in which IL-6 and ET-1 play an important role. Vitamin C can reduce these (and other) inflammatory mediators in various inflammatory conditions, and this is clinically beneficial in (non-COVID-19) hypertensive and/or diabetic obese adult patients. Considering the weight of the evidence, and because vitamin C is cheap and safe, an oral low dose (1-2 g/day) may be useful prophylactically, and in case of severe COVID-19 disease, a (very) high-dose regimen may be beneficial. Ongoing clinical trials are expected to provide more definitive evidence. A.F.F. conceived and coordinated the study; A.F.F. and W.L. contributed to the writing, reviewing and editing of the manuscript. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Clinical Features of 69 Cases with Coronavirus Disease Update Related to the Current Outbreak of COVID-19 Drug targets for corona virus: A systematic review Critical care management of adults with communityacquired severe respiratory viral infection Of chloroquine and COVID-19 Chloroquine for the 2019 novel coronavirus SARS-CoV-2 Chloroquine is a zinc ionophore Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture Does Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine/Hydroxychloroquine to Win Todays Battle Against COVID-19? Preprints Fact sheet for health care providers Emergency Use Authorization (EUA) of hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of COVID-19 in certain hospitalized patients Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention Mechanical ventilation: invasive versus noninvasive COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism Demonstration report on inclusion of hyperbaric oxygen therapy in treatment of COVID-19 severe cases ICNARC report on COVID-19 in critical care -5 Vitamin C and Infections Vitamin C intake and susceptibility to pneumonia Vitamin C and immune cell function in inflammation and cancer Vitamin C and Immune Function The effect of ascorbic acid on infection chickembryo ciliated tracheal organ cultures by coronavirus Vitamin C: an essential "stress hormone" during sepsis Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial A Review of Micronutrients and the Immune System-Working in Harmony to Reduce the Risk of Infection Vitamin C Can Shorten the Length of Stay in the ICU: A Meta-Analysis Vitamin C for preventing and treating the common cold. The Cochrane database of systematic reviews Vitamin C for preventing and treating the common cold. The Cochrane database of systematic reviews The role of exercise-induced myokines in muscle homeostasis and the defense against chronic diseases COVID-19: consider cytokine storm syndromes and immunosuppression Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. medRxiv The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19 Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? High-dose intravenous vitamin C treatment for COVID-19 Vitamin C blocks vascular dysfunction and release of interleukin-6 induced by endothelin-1 in humans in vivo Endothelin-1 and its role in the pathogenesis of infectious diseases A cytokine reborn? Endothelin-1 in pulmonary inflammation and fibrosis Endothelin and scleroderma lung disease Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors Haiming Effective Treatment of Severe COVID-19 Patients with Tocilizumab Tocilizumab for treatment of mechanically ventilated patients with COVID-19. medRxiv IL-6 and ICOS Antagonize Bim and Promote Regulatory T Cell Accrual with Age The influence of age and gender on serum dehydroepiandrosterone sulphate (DHEA-S), IL-6, IL-6 soluble receptor (IL-6 sR) and transforming growth factor beta 1 (TGF-beta1) levels in normal healthy blood donors Chronic stress and age-related increases in the proinflammatory cytokine IL-6 Age-associated increase in cytokine production during systemic inflammation: adipose tissue as a major source of IL-6. The journals of gerontology. Series A, Biological sciences and medical sciences 64 Male gender is associated with excessive IL-6 expression following severe injury Genomic analysis reveals age-dependent innate immune responses to severe acute respiratory syndrome coronavirus Increase of plasma IL-6 concentration with age in healthy subjects Age-Associated Increase in Cytokine Production During Systemic Inflammation-II: The Role of IL-1beta in Age-Dependent IL-6 Upregulation in Adipose Tissue. The journals of gerontology. Series A, Biological sciences and medical sciences Regulation of endothelin-1 release from human endothelial cells by sex steroids and angiotensin-II Age and estrogen-based hormone therapy affect systemic and local IL-6 and IGF-1 pathways in women Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerging microbes & infections 9 Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects Racial and gender differences in endothelin-1 Endothelin-1 potentiates smokeinduced acute lung inflammation Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients. medRxiv Vitamin C supplementation modulates gene expression in peripheral blood mononuclear cells specifically upon an inflammatory stimulus: a pilot study in healthy subjects Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence Intravenous Vitamin C for reduction of cytokines storm in Acute Respiratory Distress Syndrome Effect of vitamin C on inflammation and metabolic markers in hypertensive and/or diabetic obese adults: a randomized controlled trial. Drug design, development and therapy 9 Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19 Targeting potential drivers of COVID-19: Neutrophil extracellular traps COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up The antihemostatic profile of vitamin c: mechanisms that underlie the technical application of a physiological molecule Vitamin C suppresses lipopolysaccharide-induced procoagulant response of human monocyte-derived macrophages Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer PDQ® Integrative, Alternative, and Complementary Therapies Editorial Board. PDQ High-Dose Vitamin C. (National Cancer Institute Vitamin C, titrating to bowel tolerance, anascorbemia, and acute induced scurvy Pharmacokinetics of drugs used in critically ill adults Graphical abstract We thank Dr. Patrick Van Dijck for proofreading the manuscript and Alan Feyaerts for his suggestions in the creation of this article. We thank a reviewer for pointing out the increased bowel tolerance for oral vitamin C in ill patients described by Cathart, and for providing additional useful literature references.